Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
GATX GATX Corp
UAL United Airlines Holdings Inc
TEL TE Connectivity Ltd
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Price
Delayed
$13.07
Day's Change
-0.2208 (-1.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.19
Day's Low
12.84
Volume
(Light)

Today's volume of 16,349 shares is on pace to be much lighter than ATRA's 10-day average volume of 927,839 shares.

16,349

UPDATE: Stocks close higher and Nasdaq retakes 13,000 as investors aim to push past messy rotation

4:25 pm ET March 26, 2021 (MarketWatch)
Print

By Mark DeCambre

U.S. stock benchmarks closed sharply higher Friday afternoon, allowing the Dow and S&P 500 index to avoid booking a second straight weekly loss, even as rising bond yields and concerns about the global economic recovery keep investors on edge.

How did stock benchmarks perform?

On Thursday (https://www.marketwatch.com/story/dow-poised-for-slight-gain-as-stock-market-aims-to-avoid-3rd-straight-drop-11616672030?mod=market-snapshot), the Dow closed 199.42 points, or 0.6%, higher at 32,619.48, the S&P 500 rose 20.38 points to end at 3,909.52, a rise of 0.5%, while the Nasdaq Composite closed at 12,977.68, up 15.79 points for a gain of 0.1%.

For the week, the Dow notched a 1.4% increase, the S&P 500 added 1.6%, and the Nasdaq fell 0.6%.

What drove the market?

Stocks have struggled for direction in recent weeks and have been prone to intraday turbulence. Analysts have largely attributed this latest bout of volatility to month-end and quarter-end rebalancing by large pensions funds.

The impetus for that action is the rise in bond yields on expectations that the economy may stage a more potent recovery and suffer higher inflation in the wake of the $1.9 trillion fiscal stimulus package from the Biden administration.

As a bull market in bonds comes into question, big investors who adhere to traditional stocks-to-bonds portfolio diversification theories of 60% to 40% are feeling compelled to buy more fixed-income assets as yields rise and bond prices fall.

On Friday afternoon, the yield on the 10-year Treasury note yield ended slightly higher , after touching a nadir this week around 1.59%, but still below its level last Friday at 1.729%.

Markets seemed to shake off weak reports on consumer spending and income (https://www.marketwatch.com/story/gold-prices-see-muted-action-friday-as-strong-dollar-rising-yields-limit-moves-11616764647?mod=metals-stocks), with that February data showing the biggest decline in spending in 10 months due to harsh winter weather and a temporary respite in government stimulus payments. The new round of stimulus pushed through by Biden will likely lead to a big spending jump, economists believe.

Consumer spending fell 1% in February, compared with an expected drop of 0.8% and the Federal Reserve's preferred inflation gauge, personal-consumption expenditures, or PCE, rose 0.2% in February, with core inflation up 0.1%, excluding volatile energy and food, matching consensus estimates from economists surveyed by Dow Jones.

Personal income declined 7.1% in February, compared with an expected drop of 7%.

Some strategists took the readings as pointing to a transitory climb in inflation, perhaps supporting Federal Reserve Chairman Jerome Powell's belief that the central bank won't lose control of rising prices.

"Softer-than-expected PCE deflator data support the idea that Treasury yields will likely consolidate over the short-term," wrote Edward Moya, senior market analyst at Oanda, in a daily note.

Meanwhile, Americans are the most upbeat about the economy and their own financial well-being since the start of the pandemic, a new survey shows, thanks to declining coronavirus cases and more stimulus payments from Washington. The final reading of consumer sentiment in March rose to 84.9 points from 83 earlier in the month, according to a survey produced by the University of Michigan (https://www.marketwatch.com/story/americans-are-the-most-upbeat-since-the-pandemic-consumer-sentiment-survey-shows-11616768182?mod=mw_latestnews).

However, a rise in coronavirus cases that has forestalled the business reopening plans for large parts of Europe also has been credited with creating headwinds for bullish investors.

Taken together, those factors have helped create a bumpy rotation out of growth stocks that proved big winners during the pandemic and into those value shares that might perform better in an improving economy.

The S&P 500's energy sector(XLE) gained 2% for the week, while the materials sector (XLB) was up 1.9%, representing the top performing sectors on the week among the broad-market index's 11. Communication services(XLC), off 1.6%, and utilities(XLU) were the worst performers.

On Thursday, President Joe Biden announced (https://www.wsj.com/articles/president-bidens-first-press-conference-the-moments-that-mattered-11616697268)a new target for coronavirus vaccinations of 200 million doses during his first 100 days in office, which some analysts credited with Friday's upbeat trade.

"US stocks want to climb higher given the reopening trade got another boost after President Biden doubled his vaccine goal for his first 100 days," Moya said.

The Federal Reserve said on Thursday that banks won't be able to make payouts to shareholders (https://www.marketwatch.com/story/fed-says-limits-on-payouts-share-buybacks-to-end-for-most-banks-after-june-30-11616706220?mod=newsviewer_click_seemore) in the form of dividends and buybacks until June 30, as long as the institutions meet regulatory requirements, including pass stress tests. The Fed imposed restrictions on such payments at the onset of the COVID crisis. The S&P 500 financial sector(XLF) gained 1% on Friday.

In other economic reports, the U.S. trade deficit in goods widened 2.5% to $86.7 billion in February, the Commerce Department said Friday (https://www.census.gov/economic-indicators/).

Which companies were in focus?

How did other assets fare?

-Mark DeCambre; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

March 26, 2021 16:25 ET (20:25 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.